Cargando…

Practical Issues in the Use of Atezolizumab for Patients with Non-Small Cell Lung Cancer: Case Reports and Literature Review

Atezolizumab is a monoclonal antibody targeting the programmed death ligand 1 (PD-L1) that was approved in 2017 in the USA and Europe for the second-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC). This review article describes the practical clinical issues associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cobo, Manuel, Rodríguez-Abreu, Delvys, Pérez Parente, Diego, Ruiz Gracia, Pedro, González, Jorge G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140026/ https://www.ncbi.nlm.nih.gov/pubmed/33582978 http://dx.doi.org/10.1007/s40487-021-00139-3

Ejemplares similares

PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis
por: Majem, Margarita, et al.
Publicado: (2021)

PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis
por: García Campelo, María Rosario, et al.
Publicado: (2021)

Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer
por: Ardizzoni, Andrea, et al.
Publicado: (2022)

Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer
por: Ardizzoni, Andrea, et al.
Publicado: (2021)

Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
por: Isla, Dolores, et al.
Publicado: (2023)

Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database
por: Campos‐Balea, Begoña, et al.
Publicado: (2020)

Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)
por: Nadal, Ernest, et al.
Publicado: (2023)

Use of Atezolizumab for Bladder and Non–Small Cell Lung Cancers
por: Moore, Kayla Faith
Publicado: (2017)

Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma
por: Yamaguchi, Yoshitaka, et al.
Publicado: (2021)

Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature
por: Rubio-Perez, Jaime, et al.
Publicado: (2022)

“High Tumor Burden” in Metastatic Non-Small Cell Lung Cancer: Defining the Concept
por: Higuera Gómez, Oliver, et al.
Publicado: (2021)

Atezolizumab-Induced Bell’s Palsy in a Patient With Small Cell Lung Cancer
por: Kichloo, Asim, et al.
Publicado: (2020)

Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer
por: Kataoka, Nobutaka, et al.
Publicado: (2020)

Chemotherapy plus atezolizumab for a patient with small cell lung cancer undergoing haemodialysis: a case report and review of literature
por: Imaji, Mihoko, et al.
Publicado: (2021)

Atezolizumab-induced encephalitis in metastatic lung cancer: a case report and literature review
por: Arakawa, Masafumi, et al.
Publicado: (2018)

Chronic Pleuritis and Recurrent Pleural Effusion After Atezolizumab for Small Cell Lung Cancer
por: Lin, Julie, et al.
Publicado: (2021)

Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report
por: Yamakawa, Hideaki, et al.
Publicado: (2019)

Atezolizumab-Induced Stevens-Johnson Syndrome in a Patient with Non-Small Cell Lung Carcinoma
por: Chirasuthat, Phatcharawat, et al.
Publicado: (2018)

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
por: Facchinetti, Francesco, et al.
Publicado: (2018)

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
por: Seetharamu, Nagashree, et al.
Publicado: (2017)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
por: Wang, Yingcheng, et al.
Publicado: (2021)

Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients
por: Xiong, Anning, et al.
Publicado: (2021)

Lambert-Eaton Myasthenic Syndrome Caused by Atezolizumab in a Patient with Small-cell Lung Cancer
por: Kunii, Eiji, et al.
Publicado: (2021)

Atezolizumab-Induced Lambert-Eaton Myasthenic Syndrome in a Patient With Small-Cell Lung Cancer
por: Yamazoe, Masami, et al.
Publicado: (2023)

Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer
por: Rudin, C.M., et al.
Publicado: (2023)

Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Atezolizumab Post Chemo-Radiation
por: Saade, Lili Jose, et al.
Publicado: (2023)

Hope, Cure, and Adverse Effects in Immunotherapy: Atezolizumab-Associated Encephalitis in Metastatic Small Cell Lung Cancer − A Case Report and Literature Review
por: Ibrahim, Eiman Y., et al.
Publicado: (2022)

Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
por: Franco, Fernando, et al.
Publicado: (2021)

Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab
por: Taki, Takahiro, et al.
Publicado: (2020)

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
por: Herbreteau, Guillaume, et al.
Publicado: (2020)

Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer
por: Ramagopalan, Sreeram, et al.
Publicado: (2021)

Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report
por: Qiu, Guihuan, et al.
Publicado: (2022)

Atezolizumab-induced subacute cerebellar ataxia in a patient with extensive-stage small cell lung cancer
por: Chen, Chun-Chia, et al.
Publicado: (2023)

PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis
por: García-González, Jorge, et al.
Publicado: (2020)

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial
por: Provencio, Mariano, et al.
Publicado: (2022)

Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2023)

Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
por: Ryu, Rachel, et al.
Publicado: (2018)

Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients
por: Katayama, Yuki, et al.
Publicado: (2020)

The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab
por: Matsubara, Taichi, et al.
Publicado: (2020)

Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: A case report
por: Seguchi, Kyosuke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2ltnmfr971p8dq712d1hoa9arf